About Chengdu Zhongke Aoge Biotechnology
Chengdu Zhongke Aoge Biotechnology is a company based in Chengdu (China) founded in 2005 by Pan Dengke.. Chengdu Zhongke Aoge Biotechnology has raised $6.97 million across 3 funding rounds from investors including Zhenghai Capital, Luminous Ventures and Betta Pharmaceuticals. Chengdu Zhongke Aoge Biotechnology operates in a competitive market with competitors including Yecuris, zPREDICTA, Sagres Discovery, Zebrafish Lab and Xentech, among others.
- Headquarter Chengdu, China
- Founders Pan Dengke
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.97 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Zhenghai Capital
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Chengdu Zhongke Aoge Biotechnology
Chengdu Zhongke Aoge Biotechnology has successfully raised a total of $6.97M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(03 Sep 2021)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Series A - Chengdu Zhongke Aoge Biotechnology | Valuation | Luminous Ventures , Betta Pharmaceuticals |
|
| Jul, 2024 | Amount | Series A - Chengdu Zhongke Aoge Biotechnology | Valuation |
investors |
|
| Sep, 2021 | Amount | Series A - Chengdu Zhongke Aoge Biotechnology | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Chengdu Zhongke Aoge Biotechnology
Chengdu Zhongke Aoge Biotechnology has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Zhenghai Capital, Luminous Ventures and Betta Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Manages diversified investment portfolios across various asset classes for clients.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Chengdu Zhongke Aoge Biotechnology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Chengdu Zhongke Aoge Biotechnology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Chengdu Zhongke Aoge Biotechnology Comparisons
Competitors of Chengdu Zhongke Aoge Biotechnology
Chengdu Zhongke Aoge Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Yecuris, zPREDICTA, Sagres Discovery, Zebrafish Lab and Xentech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Humanized liver rodent models are developed for biology research.
|
|
| domain | founded_year | HQ Location |
Tumor-specific in vitro 3D models are supplied for drug development.
|
|
| domain | founded_year | HQ Location |
Creates innovative mouse models to analyze genes causing cancer diseases.
|
|
| domain | founded_year | HQ Location |
Zebrafish assays are utilized for preclinical and environmental evaluations.
|
|
| domain | founded_year | HQ Location |
Patient-derived xenograft models for preclinical oncology research are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Chengdu Zhongke Aoge Biotechnology
Frequently Asked Questions about Chengdu Zhongke Aoge Biotechnology
When was Chengdu Zhongke Aoge Biotechnology founded?
Chengdu Zhongke Aoge Biotechnology was founded in 2005 and raised its 1st funding round 16 years after it was founded.
Where is Chengdu Zhongke Aoge Biotechnology located?
Chengdu Zhongke Aoge Biotechnology is headquartered in Chengdu, China. It is registered at Chengdu, Sichuan, China.
Who is the current CEO of Chengdu Zhongke Aoge Biotechnology?
Lawrence Van Hoorn is the current CEO of Chengdu Zhongke Aoge Biotechnology.
Is Chengdu Zhongke Aoge Biotechnology a funded company?
Chengdu Zhongke Aoge Biotechnology is a funded company, having raised a total of $6.97M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6.97M, raised on Sep 03, 2021.
What does Chengdu Zhongke Aoge Biotechnology do?
The company was founded in 2005 in Chengdu, China, within the biotechnology sector. Xenotransplantation technology is developed for research applications, focusing on humanizing pig cells to produce organs compatible with human use. Operations involve next-generation genome engineering, somatic cell cloning, and embryo transfer techniques. Leadership includes founder Pan Dengke and CEO Lawrence Van Hoorn, with activities centered on advancing organ research solutions.
Who are the top competitors of Chengdu Zhongke Aoge Biotechnology?
Chengdu Zhongke Aoge Biotechnology's top competitors include Yecuris, zPREDICTA and Zebrafish Lab.
Who are Chengdu Zhongke Aoge Biotechnology's investors?
Chengdu Zhongke Aoge Biotechnology has 3 investors. Key investors include Zhenghai Capital, Luminous Ventures, and Betta Pharmaceuticals.